Figure 3
RvD1 enhances bacterial clearance and resolution in chronic P. aeruginosa infection synergizing with ciprofloxacin. (a-c) Bacterial load and inflammatory cell infiltrates in mice infected with RP73 agar beads (∼ 3.5 × 106 CFU/mouse) that received oral gavage with vehicle or RvD1 (100 ng/mouse) every 48 h starting from day 5 post inoculum. Numbers of live RP73 CFU, PMN, and lymphocytes were determined at 14 and 21 DPI. Quantitative resolution indices for PMN and lymphocyte removal are indicated in panels B and C. Results are mean±s.e.m. from 2 separate experiments with 10 mice/group. #P<0.05 vs. 5 DPI; *P<0.05; **P<0.01; vs. veh-treated mice. (d) Effect of ciprofloxacin on chronic P. aeruginosa lung infection. Mice infected via i.t. inoculum of agar-embedded RP73 treated with vehicle or ciprofloxacin (200, 400 μg/day, i.p.). RP73 titer in BAL and lung homogenates was determined 5 days post infection. Results are mean±s.e.m. from 7-10 mice/group. (e, f) Effect of combined RvD1 and ciprofloxacin treatment on RP73 infection, inflammation, and bacterial clearance. Bacterial load in BAL and lung homogenates and BAL cell counts were determined 5 days following inoculum of RP73 in agar beads in mice treated daily with vehicle (0.5% EtOH) or RvD1 (100 ng, os) alone or in combination with ciprofloxacin (200 μg, i.p.). Results are mean±s.e.m. from 2 separate experiments with 10–15 mice/group. *P<0.05; **P<0.01; ***P<0.001 vs. veh-treated mice.
